ClinicalTrials.gg
RecruitingNCT07402109CT-STARRSUpdated Apr 8, 2026

CBCT Guided Markerless SBRT for Renal Cell Cancer

An interventional study of Additional radiation due to imaging in Renal Cell Carcinoma (RCC), sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Carcinoma, Renal Cell with a site in Netherlands — 10 open to participants now, 21 under way, 8 of them phase 3. Carcinoma, Renal Cell · Netherlands.

Planned enrollment
65th of 83
40 · median 165
Started
2026
with 5 others
No phase
3 of 105
2 open now
Primary completion
2030-01
later than 15 of 20 live
Registered
101st of 105
by date

Among the 105 studies in Carcinoma, Renal Cell with a site in Netherlands, this one is the 65th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 101st registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 105 studies in Carcinoma, Renal Cell with a site in Netherlands are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Carcinoma, Renal Cell with a site in Netherlands, or all of them as a file.
02

Study summary

This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques

Read the detailed description

In total 40 patients will be treated for RCC using SBRT.

For 15 patients, additional breath-hold CBCT scans will be made during SBRT to investigate the intra- and inter-fraction uncertainty in breath-hold positions as well as assessing the feasibility of using surface guidance as a surrogate for target position.

Subsequently, 25 patients will be treated using the new motion management technique developed using the extra imaging data obtained from the first cohort of patients. It is hypothesized that either breath-hold or gating in combination with surface guidance will result in a reproducible (stable) position of the target and therefore minimal margins.

03

Conditions studied

  • Renal Cell Carcinoma (RCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence
  • No lesions
  • Patients must be 18 years or older
  • Ability to understand the requirements of the study and to give written , as determined by the treating physician.

Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Previous high-dose radiotherapy in the region of the kidney
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Additional imaging

    Additional CBCT scans will be made after each fraction, follow-up will be done using photon counting CT

    Radiation: Additional radiation due to imaging

Interventions

  • RadiationAdditional radiation due to imaging

    Additional imaging will be done using CT, therefore the patient will receive additional radiation dose

06

What researchers measure

Primary outcomes

  1. Reduction of renal dose

    The primary aim of this project is to minimize treatment margins, reducing the PTV, to optimally preserve renal function, while ensuring adequate tumor coverage as well as adhering to dose constraints of OARs. Primary endpoint of this study is the reduction of dose to the healthy ipsilateral kidney, defined as the ipsilateral renal volume receiving 50% of the prescribed dose (V50%).

    Time frame: At day 1 planning CTs are acquired for treatment planning. These scans will be used to make a treatment planning with standard motion management and a treatment planning will be made using novel motion management. Both plans will be compared.

Secondary outcomes

  1. Evaluate the current treatment, including the benefit of online adaptive radiotherapy

    The possible benefit of online adaptive radiotherapy will be assessed by doing an offline analysis by comparing target coverage in % between adapted and non-adapted, original plans

    Time frame: Day 1 planning CTs. Approximately day 14: start radiotherapy (3 times per week). At each fraction: CBCT. At completion of treatment (at approximately day 30) planning for adapted and non-adapted plans

  2. Investigate treatment fraction reduction

    the feasibility of transitioning from a 5×8 Gy schedule to 3×14 Gy or 1×26 Gy will be investigated by simulating the difference in the mean number of fractions when using SoC motion management and the novel motion management

    Time frame: At day 1 planning CTs are acquired for treatment planning. These will be used for treatment planning for simulated fraction schedules using standard and novel motion management

  3. Change From Baseline in Tumor Contrast Enhancement on Photon-Counting CT

    Tumor contrast enhancement measured on contrast-enhanced photon-counting CT scans. Enhancement values will be quantified within the treated lesion and reported as change from baseline.

    Time frame: Baseline (pre-treatment) and follow-up at 3, 6, and 12 months after completion of treatment

  4. Change From Baseline in Tumor Iodine Concentration on Photon-Counting CT

    Iodine concentration quantified within the treated lesion using material decomposition from contrast-enhanced photon-counting CT scans. Values will be reported as change from baseline.

    Time frame: Baseline (pre-treatment) and follow-up at 3, 6, and 12 months after completion of treatment

Other outcomes

  1. Monitor side effects

    Side-effects are assessed during treatment and follow up, according to Common Terminology Criteria for Adverse Events version 5 (CTC-AE version 5).

    Time frame: During treatment and at 3, 6, and 12 months after completion of treatment

  2. Monitor renal function

    Renal function changes will be measured using estimated glomerular filtration rate (eGFR)

    Time frame: At 3, 6, and 12 months after treatment, followed by biannual evaluations at the referring center (referring urologist) in the second year and annual assessments in the third and fourth years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2030, 45 months after the start.

Of 120 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 114. This study's planned 45 months is close to that.

Counting every sponsor, half of 127 studies reached it within 45 months; a quarter within 21 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Feb 11, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07402109
Responsible party
E. (Euphemia) A.M. Froklage (Radiation Oncologist, MD PhD, principal investigator, Erasmus Medical Center) — Principal investigator
First posted
Feb 11, 2026
Start date
Apr 1, 2026
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion